A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has ...
Initial Dose Adjustment of Zolbetuximab Plus Chemotherapy in CLDN18.2-Positive Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer (GENTLE-Z), a Randomized, Phase II Trial ...
Patients who are prescribed antibiotics during immune checkpoint blockade therapy for solid tumors face a heightened risk for ...
1don MSN
Novel immunotherapy demonstrates early potential to overcome resistance to immune checkpoint therapy
According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature ...
A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the body's immune system to target tumors. Despite their initial clinical success, many patients eventually ...
In a study published in the journal Biofunctional materials, researchers from the Wits Advanced Drug Delivery Platform (WADDP) Research Unit, Department of Pharmacy and Pharmacology, and the Division ...
Researchers have shown HIF1α as a key regulator that induces the cancer-killing capacity of T cells in hypoxic conditions. A team of researchers from the University of Alabama at Birmingham (AL, USA) ...
Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...
A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has developed a novel cancer immunotherapy strategy that forces tumors to expose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback